Savient secures US approval of Krystexxa for gout
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals has secured US FDA approval for its lead drug candidate Krystexxa (pegloticase) to treat gout in adults who do not respond to or who cannot tolerate conventional therapy. However, uncertainty still remains about the price of the drug, the timing of its launch and the size of its potential market.